Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Precision Medicine Circa 2017

May 20th 2017

Raoul S. Concepcion, MD, discusses the new era of molecular testing and screening and how it has impacted the field of prostate cancer thus far.

SouthWest Urology Uses Quality-Focused Integrated Care Mode

May 19th 2017

Michael Barkoukis, MD, and Tim Sidor, MD, started SouthWest Urology of Cleveland, OH, in 1982 from scratch with $100,000 in borrowed capital, a box of pens, and a copy machine.

Expert on Studies of the PSA Test in Prostate Cancer

May 19th 2017

Andrew Vickers, PhD, attending research methodologist at Memorial Sloan Kettering Cancer Center discusses studies of the controversial prostate-specific antigen (PSA) test for patients with prostate cancer.

Dr. Feldman on Active Surveillance in Younger Men with Prostate Cancer

May 19th 2017

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of Surgery, Harvard Medical School, discusses a study focused on active surveillance in men with prostate cancer under the age of 60.

PARP Inhibitors Attract Growing Interest in Prostate Cancer

May 16th 2017

The genomic landscape of metastatic castration-resistant prostate cancer is becoming increasingly well defined, with new clinical data emerging to clarify and, in many cases, support the use of PARP inhibitors.

Dr. Stephenson on the Quality of Life Following the Management of Localized Prostate Cancer

May 16th 2017

Andrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic discusses urinary, bowel, and sexual function following the management of localized prostate cancer.

Dr. Corn on Possibility of Immunotherapy for Patients With Prostate Cancer

May 15th 2017

Paul G. Corn, MD, PhD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the possibility of immunotherapy in patients with prostate cancer.

Dr. Loeb on Active Surveillance for Prostate Cancer

May 13th 2017

Stacy Loeb, MD, assistant professor of Urology and Population Health at New York University, discusses active surveillance for patients with low-risk prostate cancer.

Dr. Hu on the Increase in Incidence of Advanced Prostate Cancer

May 13th 2017

Jim C. Hu, MD, professor of Urology, Weill Cornell Medical College, discusses the increase in the incidence of advanced prostate cancer in the United States.

Dr. Morris on the Next Steps With Bone Biomarkers for Prostate Cancer

May 11th 2017

Michael J. Morris, MD, Memorial Sloan Kettering Cancer Center, discusses the next steps regarding bone biomarkers for patients with prostate cancer.

Dr. Dicker on DNA Sequencing for Prostate Cancer

May 10th 2017

Adam P. Dicker, MD, PhD, professor, chair, Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, discusses DNA sequencing for patients with prostate cancer.

Dr. Slovin on the Challenges of Immunotherapy in Prostate Cancer

May 9th 2017

Susan F. Slovin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the challenges of immunotherapy in prostate cancer.

Dr. Yu on the Significance of the PROTECT Study in Prostate Cancer

May 9th 2017

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses the significance of the PROTECT study results in prostate cancer.

Expert Discusses Unleashing Promise of Genetic Testing in Prostate Cancer

May 8th 2017

Christopher J. Kane, MD, discusses the challenges and impact of genetic testing on patients with prostate cancer.

Dr. Febbo on the Impact of Oncotype DX Genetic Prostate Score

May 6th 2017

Phil Febbo, MD, chief medical officer, Genomic Health, discusses the impact the Oncotype DX Genetic Prostate Score (GPS) has on patients with clinically low-risk prostate cancer.

Novel Blood Test May Identify New Biomarker in Prostate Cancer

May 5th 2017

Researchers may be able to predict which patients with CRPC are most likely to have poorer outcomes while undergoing targeted therapy, according to the results of the PREMIERE trial.

Dr. Kirsh on Advancements in Diagnosing Prostate Cancer

May 5th 2017

Gary Kirsh, MD, president of The Urology Group and the Large Urology Group Practice Association (LUGPA), discusses advancements in diagnosing patients with prostate cancer.

Novel Imaging Agent May Improve Prostate Cancer Detection

May 2nd 2017

An investigational radiotracer that targets prostate-specific membrane antigen is being tested in patients with high-risk, recurrent, or metastatic prostate cancer to determine whether the novel agent can improve upon the sensitivity and specificity of conventional imaging.

Dr. Yu on Moderate Hypofractionation in Prostate Cancer

May 2nd 2017

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses moderate hypofractionation replacing the current standard of care for patients with prostate cancer.

Abiraterone Shows Promise in Prostate Cancer After Hormone Induction Failure

April 27th 2017

Thomas Flaig, MD, discusses the study of abiraterone acetate in metastatic prostate cancer after hormone induction failure and its impact on future research in this setting.